{rfName}
Co

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Cervera Guadix, RemediosAuthorEspinosa GAuthorRíos-Garcés RAuthorCervera RAuthor

Share

January 22, 2020
Publications
>
Article
No

Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry

Publicated to:Rheumatology. 59 (6): 1306-1314 - 2020-06-01 59(6), DOI: 10.1093/rheumatology/kez419

Authors: Alijotas-Reig, Jaume; Esteve-Valverde, Enrique; Ferrer-Oliveras, Raquel; Saez-Comet, Luis; Lefkou, Elmina; Mekinian, Arsene; Belizna, Cristina; Ruffatti, Amelia; Hoxha, Ariela; Tincani, Angela; Nalli, Cecilia; Marozio, Luca; Maina, Aldo; Espinosa, Gerard; Rios-Garces, Roberto; Cervera, Ricard; De Carolis, Sara; Monteleone, Giuseppina; Latino, Omar; Udry, Sebastian; LLurba, Elisa; Garrido-Gimenez, Carmen; Trespidi, Laura; Gerosa, Maria; Chighizola, Cecilia Beatrice; Rovere-Querini, Patrizia; Canti, Valentina; Mayer-Pickel, Karoline; Tabacco, Sara; Arnau, Anna; Trape, Jaume; Ruiz-Hidalgo, Domingo; Sos, Laia; Farran-Codina, Inmaculada

Affiliations

Althaia Healthcare Univ Network Manresa, Internal Med Dept, Syst Autoimmune Dis Unit, Barcelona, Spain - Author
Althaia Healthcare University Network of Manresa - Author
Althaia Xarxa Assistencial de Manresa - Author
AO Citta Salute & Sci Torino, Dept Internal Med, Turin, Italy - Author
Azienda Ospedaliera - Universitaria Citta della Salute e della Scienza di Torino - Author
CHU Angers - Author
CNRS, INSERM Unit 6015 1083, Angers, France - Author
Dr Carlos G Durand Hosp, Autoimmune Thrombophil Dis & Pregnancy Div, Buenos Aires, DF, Argentina - Author
Fdn IRCCS Ca Granda, Obstet & Gynaecol Dept, Osped Maggiore Policlin, Milan, Italy - Author
Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Salute Donna Bambino & Sanita Pu, UOC Patol Ostet, Rome, Italy - Author
Fondazione Policlinico Universitario A. Gemelli IRCCS - Author
Hippokration General Hospital - Author
Hippokration Hosp Thessaloniki, Haematol Unit, Thessaloniki, Greece - Author
Hopital Saint-Antoine - Author
Hosp Quiron, Obstet & Gynaecol Dept, Barcelona, Spain - Author
Hospital de la Santa Creu i Sant Pau - Author
Hospital General de Agudos Carlos G. Durand - Author
Hospital Miguel Servet - Author
Hospital Universitari Vall d'Hebron - Author
IRCCS Osped San Raffaele Univ Vita Salute San Raf, Unit Med & Clin Immunol, Pregnancy & Rheumat Dis Clin, Milan, Italy - Author
Med Univ Graz, Dept Obstet, Graz, Austria - Author
Medizinische Universitat Graz - Author
Miguel Servet Univ Hosp, Internal Med Dept, Zaragoza, Spain - Author
Obstetrics and Gynaecology Department. Hospital Quirón - Author
Ospedale Maggiore Policlinico - Author
Sapienza Univ Rome, Dept Gynecol Obstet & Urol, Rome, Italy - Author
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain - Author
Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Obstet & Gynaecol Dept, Dept Med, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin, Inst Recerca Biomed August Pi & Sunyer IDIBAPS, Dept Autoimmune Dis, Barcelona, Spain - Author
Univ Brescia, Dept Clin & Expt Sci, Rheumatol & Clin Immunol Unit, Brescia, Italy - Author
Univ Cattolica Sacro Cuore, Ist Clin Ostet & Ginecol, Rome, Italy - Author
Univ Hosp Angers, Vasc & Coagulat Dept, Angers, France - Author
Univ Hosp Santa Creu & St Pau, Obstet & Gynaecol Dept, High Risk Unit, Barcelona, Spain - Author
Univ Milan, Dept Clin Sci & Community Hlth, Div Rheumatol, Milan, Italy - Author
Univ Padua, Dept Med DIMED, Rheumatol Unit, Padua, Italy - Author
Univ Torino, Dept Obstet & Gynaecol, Turin, Italy - Author
Univ Vic Cent Univ Catalonia, Althaia Healthcare Univ Network Manresa, Clin Res Unit, Barcelona, Spain - Author
Univ Vic Cent Univ Catalonia, Althaia Healthcare Univ Network Manresa, Dept Lab Med, Barcelona, Spain - Author
Univ Vic Cent Univ Catalonia, Internal Med Dept, Althaia Healthcare Network Manresa, Barcelona, Spain - Author
Universita Cattolica del Sacro Cuore, Rome - Author
Universita degli Studi di Brescia - Author
UNIVERSITA DEGLI STUDI DI MILANO - Author
Università degli studi di Roma la Sapienza - Author
Università degli Studi di Torino - Author
Universita Vita-Salute San Raffaele - Author
Universitat Autònoma - Author
Universitat Autònoma de Barcelona - Author
Universitat de Barcelona - Author
Universitat de Vic - Universitat Central de Catalunya (UVic-UCC) - Author
University of Padua - Author
UPMC Univ, Serv Med Interne & Inflammat, Immunopathol Biotherapy Dept DHU i2B, Sorbonne Univ,Hop St Antoine,AP HP, Paris, France - Author
Vall dHebron Univ Hosp, Dept Internal Med, Syst Autoimmune Dis Unit, Barcelona, Spain - Author
Vilafranca del Penedes Hosp, Androl & Male Reprod Unit, Urol Dept, Barcelona, Spain - Author
Vilafranca del Penedès Hospital - Author
See more

Abstract

To compare clinical features, laboratory data and fetal-maternal outcomes between 1000 women with obstetric APS (OAPS) and 640 with aPL-related obstetric complications not fulfilling Sydney criteria (non-criteria OAPS, NC-OAPS).This was a retrospective and prospective multicentre study from the European Registry on Obstetric Antiphospholipid Syndrome.A total of 1650 women with 5251 episodes, 3601 of which were historical and 1650 latest episodes, were included. Altogether, 1000 cases (OAPS group) fulfilled the Sydney classification criteria and 650 (NC-OAPS group) did not. Ten NC-OAPS cases were excluded for presenting thrombosis during follow-up. All cases were classified as category I (triple positivity or double positivity for aPL) or category II (simple positivity). Overall, aPL laboratory categories showed significant differences: 29.20% in OAPS vs 17.96% in NC-OAPS (P < 0.0001) for category I, and 70.8% in OAPS vs 82% in NC-OAPS (P < 0.0001) for category II. Significant differences were observed when current obstetric complications were compared (P < 0.001). However, major differences between groups were not observed in treatment rates, livebirths and thrombotic complications. In the NC-OAPS group, 176/640 (27.5%) did not fulfil Sydney clinical criteria (subgroup A), 175/640 (27.34%) had a low titre and/or non-persistent aPL positivity but did meet the clinical criteria (subgroup B) and 289/640 (45.15%) had a high aPL titre but did not fulfil Sydney clinical criteria (subgroup C).Significant clinical and laboratory differences were found between groups. Fetal-maternal outcomes were similar in both groups when treated. These results suggest that we could improve our clinical practice with better understanding of NC-OAPS patients.© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Keywords

antiphospholipidantiphospholipid antibodiesmanifestationsnon-criteria antiphospholipid syndromeobstetric antiphospholipid syndromeoutcomespregnancytreatmenttrialAdultAntibodiesAntibodies, antiphospholipidAntiphospholipidAntiphospholipid antibodiesAntiphospholipid syndromeAspirinFemaleHumansLive birthManifestationsNon-criteria antiphospholipid syndromeObstetric antiphospholipid syndromeOutcomesPregnancyPregnancy complicationsPregnancy outcomeProspective studiesRegistriesRetrospective studiesTreatmentTreatment outcomeTrial

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Rheumatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position 5/34, thus managing to position itself as a Q1 (Primer Cuartil), in the category Rheumatology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 3.49. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3.56 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 26.39 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 65
  • Scopus: 58
  • Europe PMC: 40

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 77 (PlumX).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Argentina; Austria; Colombia; France; Greece; Italy; Philippines; United States of America.